deficit in Medical Technology
Navigation Links
deficit in Medical Technology
... VYVANSE significantly improved
Attention deficit Hyperactivity Disorder (ADHD) symptoms in adults ... Shire focuses its business on attention deficit and
hyperactivity disorder (ADHD), human genetic ... (lisdexamfetamine dimesylate) (Attention deficit and
Hyperactivity Disorder ("ADHD")); the impact ...
... significant improvements in Attention deficit Hyperactivity Disorder (ADHD) symptoms in adults ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... for the treatment of the symptoms of Attention deficit Hyperactivity Disorder (ADHD). The data ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... prodrug stimulant for the treatment of Attention deficit Hyperactivity Disorder (ADHD), provided ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... study in pediatric patients with Attention deficit Hyperactivity Disorder (ADHD) showed the effect ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... in the market of VYVANSE(TM) (Attention deficit and Hyperactivity Disorder ("ADHD"); the impact ...
... system), the Attention deficit Hyperactivity Disorder (ADHD) patch, demonstrated ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...
... which demonstrated that adults with Attention deficit Hyperactivity Disorder (ADHD) experienced ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... including, but not limited to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but ...
... trial to evaluate the efficacy of NeuroAid(TM) in reducing neurological deficit and improving independence in patients in rehabilitation, with treatment ... independence and 1.7 times more likely to reduce their neurological deficit by at least 55% than patients who did not take the product. It helped ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... 674,164 949,105 Total debt and lease financing 756,477 754,099 Total stockholders' deficit (241,375) (11,902) (c) Includes $69,360 and $70,931 in restricted investments at December 31, 2008 and December ...
... of patients experience continued symptoms despite treatment. The problem with current therapies is that none of them improve the cognitive deficit in schizophrenic patients, and almost all of these drugs have significant side effects, such as weight gain, induction of tremors and psychological ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic ...
... significant improvements in Attention deficit Hyperactivity Disorder (ADHD) symptoms in adults ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... for the treatment of the symptoms of Attention deficit Hyperactivity Disorder (ADHD). The data ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... prodrug stimulant for the treatment of Attention deficit Hyperactivity Disorder (ADHD), provided ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...
... study in pediatric patients with Attention deficit Hyperactivity Disorder (ADHD) showed the effect ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... in the market of VYVANSE(TM) (Attention deficit and Hyperactivity Disorder ("ADHD"); the impact ...
... system), the Attention deficit Hyperactivity Disorder (ADHD) patch, demonstrated ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...
... which demonstrated that adults with Attention deficit Hyperactivity Disorder (ADHD) experienced ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...
Methadone Frequently Causes Menopausal Symptoms in Young Women
... methadone dependent patients were self medicating pre-existing attention deficit disorders, anxiety and depression, with opiate pain pills. Many methadone patients need treatment for attention deficit disorders, insomnia, depression, anxiety and fatigue, in addition to ...Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
... (methylphenidate transdermal system) for the treatment of Attention deficit Hyperactivity Disorder (ADHD). A request from European regulators to ... needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and ...Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...
Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, ...Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
... liabilities 243 - Stockholders' deficit (10,458) (6,106) Total liabilities and stockholders' deficit $27,082 $ 28,092 ...... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... including, but not limited to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but ...
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
... needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies ... including, but not limited to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but ...... trial to evaluate the efficacy of NeuroAid(TM) in reducing neurological deficit and improving independence in patients in rehabilitation, with treatment ... independence and 1.7 times more likely to reduce their neurological deficit by at least 55% than patients who did not take the product. It helped ...
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
... liabilities 172 - Stockholders' deficit (20,143) (6,106) Total liabilities and stockholders' deficit $15,039 $28,092 ...Nektar Therapeutics Reports Second Quarter 2009 Financial Results
... 1,317,577 1,312,796 Accumulated other comprehensive income 978 1,439 Accumulated deficit (1,187,966) (1,124,090) ---------- ---------- Total stockholders' ...... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas ...
Spherix Reports First Quarter 2009 Earnings
... 80,438 shares, at cost at March 31, 2009 and December 31, 2008 (464,786) (464,786) Accumulated deficit (18,866,456) (16,800,372) ---------- ---------- Total ...BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
... Receivables from collaborations 9,847 11,982 Total assets 72,602 84,692 Accumulated deficit (258,560) (249,268) Stockholders' equity 38,517 46,426 Note 1: Derived from audited ...Bionovo Announces First Quarter 2009 Highlights and Financial Results
... paid-in capital 59,235 59,050 Accumulated other comprehensive gain 7 24 Accumulated deficit (44,118) (39,450) Total shareholders' equity 15,132 19,632 Total ...Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
... a four-week dose titration period followed by 24 weeks of treatment. Subjects were asked to follow a hypocaloric diet representing a 500-calorie/day deficit and advised to implement a simple lifestyle modification program. About Obesity More than 300 million people worldwide and ...Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
... 44,923 30,492 Noncontrolling interest in Symphony Icon, Inc. 7,470 10,247 Accumulated deficit (508,955) (487,395) Total Lexicon Pharmaceuticals, Inc. stockholders' equity ...Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
... of Clonicel demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder (ADHD) symptoms compared to stimulant use alone. Clonicel is the company's lead compound in a pipeline of products that ...... 674,164 949,105 Total debt and lease financing 756,477 754,099 Total stockholders' deficit (241,375) (11,902) (c) Includes $69,360 and $70,931 in restricted investments at December 31, 2008 and December ...
... of patients experience continued symptoms despite treatment. The problem with current therapies is that none of them improve the cognitive deficit in schizophrenic patients, and almost all of these drugs have significant side effects, such as weight gain, induction of tremors and psychological ...
... leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic ...
Pharmasset Reports Fiscal Year End 2008 Financial Results
... Accumulated other comprehensive (loss) income (2,604) 4,405 Accumulated deficit (111,791,944) (57,134,233) Total stockholders' equity 35,187,345 ...SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
... 31, 2007, respectively 41,130 40,991 Additional paid-in capital 70,879,940 69,945,666 Accumulated deficit (61,050,605) (57,834,638) Total stockholders' equity 9,870,465 12,152,019 ...Other Contentsectothermeffectoreffectoreffectoreffectoreffectoreffectorelectromagneticelectromagneticelectromagneticelectromagneticelectromagneticelectromagneticelectroporationelectroporationelectroporationelongationelongationelongationsacsacsacsacembryoembryoembryoembryoembryoembryoembryo
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Stem cells battle for space 2How to read brain activity? 2MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 1MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 2MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 3MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 4MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 5Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 55994 1Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 55994 2Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 1Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 2Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 3
Breaking Medicine News(10 mins):Health News:Sex Talk Taking Place After the Fact 2Health News:Sex Talk Taking Place After the Fact 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Top 10 Toys That Will Scar Your Child for Life 2Health News:Thomson Reuters Releases Micromedex 2.0 2Health News:Thomson Reuters Releases Micromedex 2.0 3Health News:The Role of Mindfulness Meditation in Health Care Reform 2Health News:The Role of Mindfulness Meditation in Health Care Reform 3
Other TagsParalParalParainfluenzaParoxetineParnateParietalParathionParaphosParaneoplasticParamethadioneParalParaldehydeParainfluenzaParagonimiasisPamelorOxypurinolOxcarbazepine
Other Tagstend 2tend 3tend 4tend 5tend 6tend 7tend 8tend 9tend 10practice 2practice 3practice 4practice 5practice 6practice 7practice 8practice 9practice 10degrees 2degrees 3degrees 4degrees 5degrees 6degrees 7degrees 8degrees 9degrees 10foreign 2foreign 3foreign 4foreign 5foreign 6foreign 7foreign 8foreign 9foreign 10interactive 2sound 2sound 3sound 4sound 5sound 6| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |